Last-Hope drug access offered for desperate colitis patients
NCT ID NCT06025227
Summary
This program provides special early access to the drug etrasimod for patients with severe ulcerative colitis who have no other treatment options. It is for individuals who have tried and failed at least three other available therapies or cannot tolerate them. The program allows doctors to request the medication for single patients before it is widely approved.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.